УДК  [617.736-005.98-02:616.379-008.64]-085.357-089.855-031: 611.844.7]-06

https://doi.org/10.31288/oftalmolzh/2018/2/6769

Accidental intralenticular injection of dexametasone intravitreal implant during the treatment of refractory diabetic macular oedema

M. I. Kovtun 1, V. V. Klymenko 2, V. V. Sardaryan 3, N. M. Kovtun 1

1   City Clinical Hospital № 14 named after Prof. L. L. Gyrschman, 

   Kharkiv  (Ukraine)

2  Kharkiv National Medical University, Ophthalmology Department

   Kharkiv (Ukraine)

3    International Medical Center Oftalmika

Kharkiv (Ukraine)

This article deals with the clinical case of accidental intralenticular injection of dexamethasone implant during the treatment of refractory diabetic macula oedema. The paper is based on a comprehensive research of similar clinical cases regarding this complication. The therapy algorithm chosen by the authors is early-surgery approach with cataract phacoemulsification and relocation of Ozurdex to the vitreous body, which showed positive clinical effect.

Key words: diabetic retinopathy, diabetic macular oedema, dexamethasone intravitreal implant, complication, intralenticular Ozurdex implantation.

References

1. Prokofyeva E. Epidemiology of major eye diseases leading to blindness in Europe: a literature review / E. Prokofyeva, E. Zrenner // Ophthalmic Res. – 2012. – Vol. 47, № 4.  – P. 171-88.
2. Diabetic Retinopathy Clinical Research Network.A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Focal/Grid Photocoagulation for Diabetic Macular Edema // Ophthalmology. – 2008. – Vol. 115, № 9. – p. 1447-9.
3. Cunningham E.T. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema / E.T.Cunningham , A.P. Adamis , M. Altaweel, L.P. Aiello, N.M. Bressler, D.J. D'Amico, M. Goldbaum, D.R. Guyer, B. Katz, M. Patel, S.D Schwartz  // Ophthalmology. – 2005. – Vol. 112, №10. – P. 1747-57.
4. http://www.ozurdex.com/DME/About-DME 
5. Coca-Robinot J. Accidental injections of dexamethasone intravitreal implant (Ozurdex) into the crystalline lens / J. Coca-Robinot, B. Casco-Silva, F. Armad?-Maresca, J. Garc?a-Mart?nez // Eur J Ophthalmol – 2014. – Vol. 24. – P. 633-6.
6. Berarducci A. Inadvertent dexamethasone implant injection into the lens body management /  A. Berarducci, I.S. Sian, R. Ling // Eur J Ophthalmol. – 2014. – Vol.24, №4. – P. 620-2.
7. Baskan B. Ozurdex completely located inside a crystallized lens - Results of 14 months / B. Baskan, A. C?cek, A. Gulhan, M. Gundogan, S. Goktas // American Journal of Ophthalmology. – 2016. – Vol. 4. – P. 38-40
8. Poornachandra B. Immortal Ozurdex: A 10-month follow-up of an intralenticularimplant / B. Poornachandra, V. Kumar, C. Jayadev, S.H. Dorelli, N.K. Yadav, R. Shetty // Indian J Ophthalmol. – 2017. – Vol. 65, №3. – P. 255-257.